

November 9, 2018
SymBio Pharmaceuticals Limited
Fuminori Yoshida
Representative Director
President and Chief Executive Officer
(Securities Code: 4582)

Notice Concerning Non-operating Income

SymBio Pharmaceuticals Limited (“the Company”) announces accrued non-operating income for the third quarter of the fiscal year ending December 31, 2018 (from July 1, 2018 to September 30, 2018) as follows.

1. Details of Non-operating Income

The Company recorded a foreign exchange gain of 30,469 thousand yen under non-operating income for the third quarter of the fiscal year ending December 31, 2018 (from July 1, 2018 to September 30, 2018) due to recent fluctuations in foreign exchange rates. In addition, with a foreign exchange loss of 29,002 thousand yen for the first half ended June 30, 2018, a total foreign exchange gain of 1,466 thousand yen was recorded in the Statements of income for the third quarter (cumulative) of the fiscal year ending December 31, 2018.

2. Future Outlook

Based on its assumption concerning operational trends for this fiscal year, the Company determined that this non-operating income would have no significant impact on the results of operations for the year with no modification to the financial forecast required. The Company will make a prompt announcement should any modification to the financial forecast be necessary.

[Contact]

Investor Relations
Tel: +81(0)3 5472 1125